

Nevada Medicaid

Submit fax request to: 855-455-3303
Please note: All information below is required to process this request.

Immunomodulator Drugs Prior Authorization Request Form

Member Information (required)				Provider Information (required)				
Member Name:			Provider Name:					
Insurance ID#:			NPI	PI#: Specialty:				
Date of Birth:			Office Phone:					
Street Address:			Office Fax:					
City: State: Zip:				Office Street Address:				
Phone:			City			State:	Zip:	
Thone.						Olate.	Διγ.	
		Medication	Info	ormation (re	quired)			
Medication Name:				Strength:		Dosag	e Form:	
			Directions for Use:					
☐ Check if request is for cor	ntinuation of th							
		Clinical In	forr	nation (requi	red)			
Clinical information requ								
☐ The recipient has had a negative tuberculin test								
☐ The recipient does not have an active infection or a history of recurring infections								
☐ Only one biologic medication is being used								
Rheumatoid Arthritis:								
☐ The recipient has a diagnosis of moderately to severely active RA								
☐ The recipient is 18 years of age or older								
☐ The recipient has had a	_	y consultation, inc	luding	g the date of the	visit:		_	
Choose one of the followi	_							
□ The recipient has had RA for < six months (early RA) and has high disease activity; and an inadequate or adverse reaction to a disease modifying antirheumatic drug (DMARD) (methotrexate, hydroxychloroquine, leflunomide, minocycline and sulfasalazine)								
☐ The recipient has had F and has an inadequat sulfasalazine)		,		_	,			
☐ The recipient has had F	RA for > six m	onths (intermediate	e or lo	ong-term diseas	se duration) a	nd has high	n disease activity	
Psoriatic Arthritis:		•		3	,	J	,	
☐ The recipient has a diag	gnosis of mod	erate or severe ps	oriati	c arthritis				
☐ The recipient is 18 year	rs of age or ol	der						
☐ The recipient has had a rheumatology consultation including the date of the visit or a dermatology consultation including the date of the visit:								
☐ The recipient had an ina (NSAID) or to any one					•		•	
Ankylosing Spondylitis.								
☐ The recipient has a diag	gnosis of anky	losing spondylitis						
☐ The recipient is 18 years of age or older								
☐ The recipient has had an inadequate response to NSAIDs								
☐ The recipient has had an inadequate response to any one of the DMARDs (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline)								

FA-157 06/06/2022 Page 1 of 3

Clinical Information Cont. (required)
Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis:
☐ The recipient has a diagnosis of moderately or severely active juvenile RA or juvenile idiopathic arthritis
☐ The recipient is at an appropriate age, based on the requested agent:
Abatacept: Six years of age or older
 Adalimumab, canakinumab, etanercept, tocilizumab: Two years of age or older
☐ The recipient has at least five swollen joints
☐ The recipient has three or more joints with limitation of motion and pain, tenderness, or both
☐ The recipient has had an inadequate response to one DMARD
Plaque Psoriasis:
☐ The recipient has a diagnosis of chronic, moderate to severe plaque psoriasis
☐ The recipient is 18 years of age or older
☐ The agent is prescribed by a dermatologist
☐ The recipient has failed to adequately respond to a topical agent
☐ The recipient has failed to adequately respond to at least one oral treatment
Crohn's Disease:
☐ The recipient has a diagnosis of moderate to severe Crohn's Disease
☐ The recipient is at an appropriate age, based on the requested agent:
Humira: Five years of age or older
Infliximab: Six years of age or older
All others: 18 years of age or older
☐ The recipient has failed to adequately respond to one or more conventional therapies (e.g., sulfasalazine, mesalamine,
antibiotics, corticosteroids, azathioprine, 6-mercaptopurine, leflunomide); or □ The recipient has fistulizing Crohn's Disease
Ulcerative Colitis (UC):
☐ The recipient has a diagnosis of moderate to severe ulcerative colitis
☐ The recipient has a diagnosis of moderate to severe discretive control. ☐ The recipient is at an appropriate age, based on the requested agent:
Humira: Five years of age or older
Infliximab: Six years of age or older
All others: 18 years of age or older
☐ The recipient has failed to adequately respond to one or more of the following standard therapies: Corticosteroid, 5-
Aminosalicylic acid agents, immunosuppressants and/or Thiopurines
Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndromes (FCAS) or Muckle-
Wells Syndrome (MWS)
☐ The recipient has a diagnosis of FCAS or MWS
☐ The recipient is at an appropriate age, based on the requested agent:
Canakinumab: Four years of age or older
Rilonacept: 12 years of age or older
Cryopyrin-Associated Periodic Syndromes (CAPS): Neonatal-Onset Multisystem Inflammatory Disease (NOMID):
☐ The recipient has a diagnosis of NOMID
Drug Specific Criteria:
Zeposia® (ozanimod)
☐ The recipient has a diagnosis of moderately to severely active ulcerative colitis
☐ Prescribed by or in consultation with a gastroenterologist
☐ The recipient has failed to adequately respond after a 90-day trial to one or more conventional therapies (e.g.,
sulfasalazine, aminosalicylates, 6-mercaptopurine, corticosteroids, azathioprine)
☐ The recipient has tried and failed two preferred immunomodulator therapies indicated for moderately to severely active ulcerative colitis

FA-157 06/06/2022 Page 2 of 3

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

For urgent or expedited requests please call 1-800-711-4555. This form may be used for non-urgent requests and faxed to 1-800-527-0531.

FA-157 06/06/2022 Page 3 of 3